Your session is about to expire
← Back to Search
Unknown
IMB-1018972 for Hypertrophic Cardiomyopathy (IMPROVE-HCM Trial)
Phase 2
Waitlist Available
Research Sponsored by Imbria Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through week 14 safety follow-up
Awards & highlights
Summary
This trial is testing a new drug for people with non-obstructive HCM to see if it is safe and effective.
Eligible Conditions
- Hypertrophic Cardiomyopathy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through week 14 safety follow-up
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through week 14 safety follow-up
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs
Secondary outcome measures
Oxygen
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: IMB-1018972 200mgExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IMB-1018972
2021
Completed Phase 2
~130
Find a Location
Who is running the clinical trial?
Imbria Pharmaceuticals, Inc.Lead Sponsor
3 Previous Clinical Trials
748 Total Patients Enrolled
Paul Chamberlin, MDStudy DirectorImbria Pharmaceuticals, Inc.
6 Previous Clinical Trials
1,887 Total Patients Enrolled
Medical MonitorStudy ChairImbria Pharmaceuticals, Inc.
1,672 Previous Clinical Trials
988,401 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger